ViroGates notification of transactions by persons discharging managerial responsibilities according to MAR art. 19

15.7.2022 13:45:01 CEST | ViroGates | Managers' transactions

COMPANY ANNOUNCEMENT - No. 19-2022 - Inside Information - 15 July 2022

BIRKERØD, DENMARK - ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, today received notice of the following transactions by persons discharging managerial responsibilities according to MAR art. 19. The transaction notification form is listed below.

The shares subscribed by CEO Jakob Knudsen according to this notification are shares purchased in the rights emission. Jakob Knudsen has also undertaken to subscribe for shares in an emission based on warrants as reported in company announcement no. 17 announced on 7^th July 2022. The reporting of this transaction is expected to take place next week when the shares are issued.

1.	Nærmere oplysninger om personen med ledelsesansvar/personen med nær tilknytning til denne
a)	Navn	Jakob Knudsen
2.	Årsag til indberetningen
a)	Stilling/titel	Administrerende direktør
b)	Første indberetning/ændring	Ændring
3.	Nærmere oplysninger om udstederen, deltageren på markedet for emissionskvoter, auktionsplat- formen, auktionsholderen eller den auktionstilsynsførende
a)	Navn	ViroGates A/S
b)	LEI-kode	5493007TX8XS56RMZD94
4.	Nærmere oplysninger om transaktionen/transaktionerne: gentages for i) hver type instrument, ii) hver type transaktion, iii) hver dato og iv) hvert sted, hvor der er udført transaktioner
a)	Beskrivelse af det finansielle instrument, instru menttypen   Identifikationskode	Aktier       DK0061030574
b)	Transaktionens art	Køb
c)	Pris(er) og mængde(r)		Pris(er)	Mængde(r)
			60	6845
d)	Aggregerede oplysninger Aggregeret mængde Pris	6845 DKK 410.700
e)	Dato for transaktionen	14/07-2022
f)	Sted for transaktionen	Nasdaq First North Growth Market Denmark (DSME)

This announcement is also available on the company’s website.

For further information, please contact:

ViroGates A/S:

CEO, Jakob Knudsen

Tel. [phone], email: [e-mail]

Certified Advisor:

Västra Hamnen Corporate Finance

Per Lönn

Tel. [phone], email: [e-mail]

About ViroGates

ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff.

The company was founded in 2000. Headquartered in Denmark, ViroGates’ sales force covers the Nordics, Spain, and France, while distributors serve other markets. ViroGates’ shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.

 

Disclosure regulation

Prospects about the future reflect ViroGates' current expectations for future events and results. The statements are by nature inherent in risks, uncertainties and other matters that are difficult to predict or out of control. The actual results may therefore differ from the expectations expressed.

Contacts

• Jakob Knudsen, CEO, [phone], [e-mail]

Attachments

• 20220715 FT indberetning ledende medarbejder JK.pdf

© Ritzau Denmark, source Ritzau English Regulatory Releases